MA27929A1 - Utilisation de calcitonine pour le traitement de l'osteoarthrite - Google Patents

Utilisation de calcitonine pour le traitement de l'osteoarthrite

Info

Publication number
MA27929A1
MA27929A1 MA28746A MA28746A MA27929A1 MA 27929 A1 MA27929 A1 MA 27929A1 MA 28746 A MA28746 A MA 28746A MA 28746 A MA28746 A MA 28746A MA 27929 A1 MA27929 A1 MA 27929A1
Authority
MA
Morocco
Prior art keywords
osteoarthritis
calcitonin
treatment
mammals
treating
Prior art date
Application number
MA28746A
Other languages
English (en)
Inventor
Moise Azria
Claus Christiansen
Simon David Bateman
Shoufeng Li
Original Assignee
Novartis Ag
Nordic Bioscience As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34135096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27929(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Nordic Bioscience As filed Critical Novartis Ag
Publication of MA27929A1 publication Critical patent/MA27929A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Nouvelle utilisation de la calcitonine pour le traitement de l'ostéoarthrite et méthodes de traitement et / ou de prévention de l'ostéoarthrite chez des mammifères, en particulier des êtres humaines.
MA28746A 2003-07-23 2006-01-23 Utilisation de calcitonine pour le traitement de l'osteoarthrite MA27929A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48940003P 2003-07-23 2003-07-23

Publications (1)

Publication Number Publication Date
MA27929A1 true MA27929A1 (fr) 2006-06-01

Family

ID=34135096

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28746A MA27929A1 (fr) 2003-07-23 2006-01-23 Utilisation de calcitonine pour le traitement de l'osteoarthrite

Country Status (22)

Country Link
US (3) US7749954B2 (fr)
EP (2) EP1651249B1 (fr)
JP (2) JP4716987B2 (fr)
KR (1) KR101070036B1 (fr)
CN (1) CN1856321B (fr)
AU (2) AU2004262906B2 (fr)
BR (1) BRPI0412265A (fr)
CA (1) CA2532565C (fr)
ES (2) ES2398237T3 (fr)
IL (2) IL173002A (fr)
IS (1) IS8316A (fr)
MA (1) MA27929A1 (fr)
MX (1) MXPA06000807A (fr)
NO (1) NO330867B1 (fr)
NZ (1) NZ544645A (fr)
PL (2) PL1651249T3 (fr)
PT (2) PT1651249E (fr)
RU (1) RU2368390C2 (fr)
TN (1) TNSN06022A1 (fr)
TW (1) TWI343816B (fr)
WO (1) WO2005014031A1 (fr)
ZA (1) ZA200600373B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04005080A (es) * 2004-05-27 2005-11-30 Aspid S A De C V Una composicion moduladora de la inflamacion articular cronica a base de colagena-polivinilpirrolidona.
PE20100241A1 (es) 2005-09-19 2010-04-16 Emisphere Tech Inc Formas cristalinas de la sal di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
RU2469709C2 (ru) 2005-11-17 2012-12-20 Новартис Аг Фармацевтическая композиция
AU2007289344B2 (en) 2006-08-31 2011-04-14 Novartis Ag Pharmaceutical compositions comprising hGH for oral delivery
KR20150091536A (ko) * 2007-03-02 2015-08-11 노파르티스 아게 칼시토닌의 경구 투여
EP2460515B1 (fr) * 2007-08-09 2017-03-08 Novartis AG Compositions à base de calcitonine orale et leurs applications
NZ585080A (en) 2007-11-02 2012-05-25 Emisphere Tech Inc Composition comprising Vitamin B12 and N-[8-(2-hydroxybenzoyl) amino ]caprylic acid and salts thereof for treating Vitamin B12 deficiency
RU2494755C2 (ru) 2008-08-18 2013-10-10 Интера Био Лтд. Способы и композиции для перорального введения белков
RU2537181C2 (ru) * 2009-03-12 2014-12-27 Нордик Байосайенс А/С Лечение диабета и метаболического синдрома
ES2583259T3 (es) 2009-12-01 2016-09-20 Novo Nordisk A/S Nuevas liasas alfa-amidantes de peptidil alfa-hidroxiglicina
US20120071410A1 (en) 2010-09-21 2012-03-22 Unigene Laboratories Inc. Calcitonin products and therapies for treating inflammatory or degenerative diseases
BR112014010701A2 (pt) 2011-11-02 2020-06-23 Keybioscience Ag Uso de um peptídeo
EP2773365B1 (fr) 2011-11-02 2016-07-20 KeyBioscience AG Utilisation de mimétiques de la calcitonine pour le traitement de certaines maladies et affections
ES2797452T3 (es) * 2012-03-16 2020-12-02 Fertility Innovations Ltd Procesamiento de espermatozoides
ES2660788T3 (es) 2013-11-14 2018-03-26 Keybioscience Ag Miméticos de la calcitonina para el tratamiento de enfermedades y trastornos
CN104095828A (zh) * 2014-07-29 2014-10-15 中国药科大学 一种降钙素口服肠溶组合物及其制备方法
GB201500263D0 (en) 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
KR20190036903A (ko) 2017-09-28 2019-04-05 (주)휴럼 리트세노라이드를 유효성분으로 하는 염증과 골관절염에 대한 예방 및 치료용 약학 조성물
US11274158B2 (en) * 2018-01-30 2022-03-15 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators
CN108586601B (zh) * 2018-05-14 2021-07-27 四川大学 一种骨靶向性鲑鱼降钙素及其制备方法
GB201813678D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
GB201813677D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
JP2023515886A (ja) 2020-03-02 2023-04-14 マジック リープ， インコーポレイテッド 没入型のオーディオプラットフォーム

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US608618A (en) 1898-08-09 Thomas millen
HU203204B (en) 1987-09-15 1991-06-28 Sandoz Ag Process for producing suppository containing calcitonin and taurocholic acid
JP3501471B2 (ja) 1992-06-15 2004-03-02 旭化成ファーマ株式会社 カルシトニン類の安定化組成物および安定化法
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
GB9623205D0 (en) * 1996-11-07 1997-01-08 Eurand Int Novel pharmaceutical compositions
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP1175390B1 (fr) 1999-04-05 2005-02-02 Emisphere Technologies, Inc. Sels disodiques, monohydrates et solvates ethanol pour liberer des agents actifs
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6436990B1 (en) 1999-10-27 2002-08-20 Nobex Corporation 6-methoxy-2-naphthylacetic acid prodrugs
US20020012459A1 (en) * 2000-06-22 2002-01-31 Chips Brain Co. Ltd. Method and apparatus for detecting stereo disparity in sequential parallel processing mode
AU2001285489A1 (en) 2000-08-29 2002-03-13 Nobex Corporation 5-ASA derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith
EP1404654A4 (fr) 2000-10-25 2008-12-03 Smithkline Beecham Corp Composes calcilytiques
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
US6479692B1 (en) 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
EP1420827B8 (fr) 2001-08-17 2009-12-23 Novartis AG 5-cnac utilise en tant qu'agent d'administration par voie orale pour des fragments d'hormone parathyroidienne

Also Published As

Publication number Publication date
WO2005014031A1 (fr) 2005-02-17
EP2316473A1 (fr) 2011-05-04
NZ544645A (en) 2009-04-30
IS8316A (is) 2006-02-21
JP2006528152A (ja) 2006-12-14
AU2008202879B2 (en) 2012-05-24
ES2398237T3 (es) 2013-03-14
US7749954B2 (en) 2010-07-06
RU2006105479A (ru) 2007-09-10
CA2532565A1 (fr) 2005-02-17
ZA200600373B (en) 2007-01-31
IL227988A (en) 2016-10-31
KR101070036B1 (ko) 2011-10-04
ES2436152T3 (es) 2013-12-27
TNSN06022A1 (en) 2007-10-03
NO330867B1 (no) 2011-08-01
JP2011121987A (ja) 2011-06-23
CN1856321A (zh) 2006-11-01
JP4716987B2 (ja) 2011-07-06
PL1651249T3 (pl) 2013-04-30
EP2316473B1 (fr) 2013-08-21
US20100278881A1 (en) 2010-11-04
CA2532565C (fr) 2012-05-08
BRPI0412265A (pt) 2006-09-05
US20060194722A1 (en) 2006-08-31
PT1651249E (pt) 2012-12-21
KR20060034298A (ko) 2006-04-21
RU2368390C2 (ru) 2009-09-27
MXPA06000807A (es) 2006-08-23
EP1651249A1 (fr) 2006-05-03
IL173002A (en) 2013-09-30
CN1856321B (zh) 2012-10-03
US20140271735A1 (en) 2014-09-18
AU2004262906B2 (en) 2008-04-03
PT2316473E (pt) 2013-09-20
IL173002A0 (en) 2006-06-11
PL2316473T3 (pl) 2014-05-30
AU2004262906A1 (en) 2005-02-17
HK1152229A1 (en) 2012-02-24
TW200518769A (en) 2005-06-16
HK1089935A1 (en) 2006-12-15
NO20060890L (no) 2006-04-24
AU2008202879A1 (en) 2008-07-24
TWI343816B (en) 2011-06-21
US8765675B2 (en) 2014-07-01
EP1651249B1 (fr) 2012-09-12
IL227988A0 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
MA27929A1 (fr) Utilisation de calcitonine pour le traitement de l'osteoarthrite
ATE395458T1 (de) Lineare polyamino- und/oder polyammonium- polysiloxancopolymere ii
DE60019473D1 (de) (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien
EP1453505A4 (fr) Utilisation de pramipexole pour traiter la sclerose laterale amyotrophique
BR0316000A (pt) Copolìmeros lineares de poliamino- e/ou poliamÈnio-polissiloxano i
ATE254461T1 (de) Behandlung von augenschmerzen
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
DE60043868D1 (de) Abgeschwächte Mikroorganismen für die Behandlung von Infektionen
TR200000756T2 (tr) Davranış bozukluğu tedavisi.
DE60008143D1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
FR2834459B1 (fr) Agent microbicide et composition de traitement cosmetique le contenant
EE05357B1 (et) Tablett, mis sisaldab v„hemalt kahte eristatavat segmenti, ning selle kasutamine
DK1463735T3 (da) Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider
DK1392355T3 (da) Anvendelse af proteasominhibitorer tilbehandling af öjentörhedslidelser
YU89103A (sh) Novi postupak lečenja opsesivno-kompulsivnog poremećaja (okp) i poremećaja povezanih sa okp-om, korišćenjem gvg-a
TR200200278T2 (tr) Kalsilitik bileşimler
ATE347888T1 (de) Verwendung von aivlosin zur behandlung und prevention der lawsonia-infektionen in schweinen.
FR2786100B1 (fr) Nouvelle application therapeutique de la nicergoline
BRPI0411382A (pt) derivados de 2-aminobenzoil
WO2003092701A3 (fr) Utilisation d'acides amino-alcane-phosphoniques substitués
FR2938429B1 (fr) Utilisation cosmetique de microorganisme(s) pour le traitement des desordres du cuir chevelu
DZ3320A1 (fr) Complexe comprenant de l'eletriptane et de la sulphobutylether-cyclodextrine pour le traitement de la migraine
DZ3449A1 (fr) Composition sous forme d'emulsion appropriee pour le traitement de l'hyperhidrose et/ou bromhidrose plantaire.
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.
ATE302009T1 (de) Ubichinon qn zur behandlung von migräneschmerzen